EPHX2 and colorectal carcinoma: Given sEH as a novel therapeutic target in the pathogenesis of colonic inflammation and CRC, it is important to develop novel combined treatment of ω-3 PUFAs with sEH pharmacological inhibitors to suppress colonic inflammation and CRC.